作者：
Kai,Rejeski [1]
;
Andreas,Burchert [2]
;
Gloria,Iacoboni [3]
;
Pierre,Sesques [4]
;
Lars,Fransecky [5]
;
Veit,Bücklein [6]
;
Corinna,Trenker [7]
;
Rafael,Hernani [8]
;
Ralph,Naumann [1]
;
Jonas,Schäfer [2]
;
Viktoria,Blumenberg [4]
;
Christian,Schmidt [9]
;
Kristina,Sohlbach [10]
;
Michael,von Bergwelt-Baildon [4]
;
Emmanuel,Bachy [1]
;
Pere,Barba [2]
;
Marion,Subklewe [3]
作者单位：
Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany.
[1]
Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
[2]
German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
[3]
Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
[4]
Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
[5]
Department of Medicine, Universitat Autònoma of Barcelona (UAB), Bellaterra, Spain.
[6]
Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France.
[7]
Medical Department II-Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.
[8]
Department of Hematology, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Spain; and.
[9]
Medical Department III-Hematology and Oncology, St. Marien-Krankenhaus Siegen, Siegen, Germany.
[10]
DOI
10.1182/bloodadvances.2022007776
PMID
35793454
发布时间
2022-11-05
换一批
换一批
